MP diagnostic tests have been performed on tumor specimens of patients who met the inclusion criteria with invasive BC, HR+/HER2‐, staged T1‐2, lymph node‐negative or 1–3 metastases from the StGallen recommendations.[29] Patients are categorized into high‐risk and low‐risk based on the risk values of the genomic MP test (Figures S1c,S2b, Supporting Information). Here, ERBB2 is linked to breast cancer.